Qiagen (QGEN) announced it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin, Genoox’s flagship cloud-based community platform, to the QIAGEN Digital Insights portfolio, strengthening QIAGEN’s leadership in genetic interpretation for clinical genomics applications. The platform is currently used by more than 4,000 healthcare organizations in over 50 countries and has powered more than 750,000 case interpretations to date. QIAGEN has acquired Genoox for $70 million in cash and eligible for additional milestone payments of up to $10 million. The acquisition is expected to generate approximately $5 million of sales in 2025 for QIAGEN and have a neutral impact on adjusted EPS.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen’s Balanced Outlook: Hold Rating Amidst Strong Performance and Valuation Concerns
- Qiagen price target lowered to EUR 42 from EUR 45 at Morgan Stanley
- QIAGEN Reports Strong Q1 2025 Results and Plans Dividend Initiation
- QIAGEN Reports Strong Q1 2025 Earnings
- Qiagen’s Strong Q1 2025 Earnings Call Highlights Growth and Confidence